Cognizant Technology Solutions
CTSH
$66.36
+0.21%
Cognizant Technology Solutions is a multinational IT services and consulting provider delivering digital transformation, application development and maintenance, business process outsourcing, and AI-enabled engineering services to enterprise clients, with deep concentration in financial services, healthcare, and communications/media/technology verticals. The company is a scaled tier-1 incumbent in the global IT services industry, distinguished by a US-headquartered, India-centric global delivery model that competes directly with Accenture, Infosys, TCS, and Wipro on large multi-year outsourcing contracts while positioning itself as a consultative, industry-specialized partner rather than a pure labor arbitrage vendor. The current investor narrative centers on whether Cognizant can reaccelerate organic growth toward mid-single digits while defending margins against AI-driven pricing pressure and client discretionary spending caution, with the stock's violent 2026 drawdown and subsequent sharp recovery reflecting a debate over whether the selloff was an overreaction to soft bookings and guidance or a structural de-rating of legacy IT services. Recent quarterly results showing modest 4.5% YoY revenue growth, disciplined cost control, and aggressive capital return via buybacks have fueled a re-rating, though the market remains split on the durability of the rebound given persistent questions about GenAI cannibalization of traditional services revenue.…
CTSH
Cognizant Technology Solutions
$66.36
Related headlines
Investment Opinion: Should I buy CTSH Today?
Rating: Hold. The core thesis is that Cognizant is a cheap, cash-generative value stock (11.13x forward PE, $2.598 billion TTM FCF) whose 55% three-month rally has already captured most of the near-term re-rating, leaving the risk/reward balanced at $70.54 against a consensus target of $66.66 and a Buy rating with a mean of 2.21 from 25 analysts. Supporting evidence is genuinely strong on valuation and balance sheet: the 11.13x forward multiple versus 18.20x trailing implies 39% EPS growth to $6.26, the 0.105 debt-to-equity and 2.34 current ratio eliminate solvency concerns, buybacks cut diluted shares 6.2% from 497 million to 466 million, and operating margin held near 16% with gross margin recovering to 33.37%. However, the 4.5% revenue growth and 1.3% sequential expansion are too weak to justify chasing the stock after a 55% run, and the 9.49x EV/EBITDA and 1.52x EV/Sales, while cheap versus peers, are consistent with a below-peer growth profile rather than a mispricing. The biggest risks that could invalidate the thesis are a GenAI-driven pricing shock in Financial Services and Healthcare, a forward EPS miss below $6.00, and continued share loss to Accenture and the Indian tier-1s. This Hold would upgrade to Buy if the stock pulls back toward the $60-$63 area (roughly 10x forward EPS) or if Q3 bookings show acceleration above 5% growth; it would downgrade to Sell if revenue growth decelerates below 3% or gross margin falls under 30%. On balance the stock is fairly valued to modestly cheap versus its own history, but no longer the deep-value opportunity it was at $37-$47.
Sign up to view all
CTSH 12-Month Price Forecast
The forward-looking view is genuinely balanced: the valuation is cheap on forward earnings and the balance sheet is pristine, but the 55% three-month rally has closed the gap to consensus fair value and the 4.5% growth rate offers no fundamental catalyst for further multiple expansion. The 25% bull / 50% base / 25% bear probability distribution reflects that the base case of range-bound trading around $63-$72 is most likely, with the wide $47-$93 target dispersion capturing genuine uncertainty about GenAI's impact on legacy revenue. I would upgrade to bullish if Q3 bookings show acceleration above 5% or the stock pulls back to $60-$63 (roughly 10x forward EPS), and downgrade to bearish if revenue growth decelerates below 3% or gross margin breaks under 30%. The key watch item is whether the $6.26 forward EPS estimate survives the next two earnings reports intact.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cognizant Technology Solutions's 12-month outlook, with a consensus price target around $68.86 and implied upside of +3.8% versus the current price.
Average Target
$68.86
0 analysts
Implied Upside
+3.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$47 - $93
Analyst target range
Coverage is broad with 25 analysts, and the consensus recommendation is Buy with a mean rating of 2.21 on a scale where lower is more bullish. The average target price of $66.66 sits below the current $70.54, implying roughly -5.5% downside to consensus, a notable signal that the stock has run past the Street's fair value estimates during its 55% three-month rally. The distribution of recent institutional ratings is more cautious than the headline Buy suggests: of the ten most recent actions, only Deutsche Bank (Buy), Guggenheim (Buy), JP Morgan (Overweight), Wells Fargo (Overweight), and Susquehanna (Positive) are constructive, while TD Cowen (Hold), Citigroup (Neutral), Morgan Stanley (Equal Weight), and RBC (Sector Perform) cluster in neutral territory, and no firm has upgraded or downgraded recently, indicating stable but unenthusiastic sentiment. The target range is extremely wide, from a low of $47.00 to a high of $93.00, a spread of roughly 98% of the low, which signals high uncertainty about Cognizant's growth trajectory. The $93 high target implies roughly 32% upside from $70.54 and would require multiple expansion toward the mid-teens forward PE plus confidence in accelerating bookings and AI-driven deal wins; the $47 low target implies roughly 33% downside and prices in margin compression, continued share loss to larger peers, and a return to the growth-scare de-rating that drove the stock to $37 in June. With the average target below the current price and a wide dispersion, the analyst community is effectively signaling that the recent rally has captured much of the near-term upside, and the risk/reward from here is balanced at best pending confirmation of the forward EPS estimate of $6.26 and revenue of $24.74 billion.
Bulls vs Bears: CTSH Investment Factors
The bull case currently has stronger near-term evidence: the 11.13x forward PE, fortress balance sheet, 6.2% share-count reduction from buybacks, and 55% momentum surge all point to a value re-rating in progress. However, the bear case is structurally credible — 4.5% revenue growth with no sequential acceleration, GenAI cannibalization risk in the two largest verticals, and a stock now trading 5.5% above the consensus target all argue the rebound has overshot fundamentals. The single most important tension is whether the $6.26 forward EPS estimate is achievable: if buybacks and margin discipline deliver it, the 11.1x multiple is too cheap and the stock re-rates toward the $93 high target; if growth stalls below 4% and AI pricing pressure compresses margins, the forward estimate gets cut and the stock retests the $47 low target. Everything hinges on bookings and GenAI deal conversion over the next two quarters.
Bullish
- Forward PE of 11.1x is deeply discounted: At $70.54, CTSH trades at 11.13x forward EPS of $6.26 versus 18.20x trailing, a 39% compression that prices in substantial earnings growth. For a company generating $2.598 billion in TTM free cash flow and $636 million of quarterly net income, this multiple sits at the low end of the 14x-18x band the stock held through 2024-2025.
- Explosive momentum with 55% three-month gain: The stock has rallied 55.20% over three months and 19.28% over one month, versus SPY's 2.85% and -1.02% respectively, producing relative strength of +52.35% and +20.30%. This is a violent mean-reversion off the $37.08 low, and the shares have reclaimed roughly 66.8% of the 52-week range.
- Fortress balance sheet with minimal leverage: Debt-to-equity of just 0.105, a current ratio of 2.34, and interest coverage above 100x (Q2 2026 interest expense of only $13 million against $874 million operating income) leave essentially no solvency risk. The $1.038 billion cash balance plus $558 million of quarterly operating cash flow fully funds the growth and capital-return program.
- Aggressive buybacks shrinking share count: Cognizant deployed $1.163 billion into buybacks in Q2 2026 alone, and diluted shares fell from 497 million in Q4 2024 to 466 million in Q2 2026, a 6.2% reduction. This mechanical EPS tailwind supports the $6.26 forward estimate even with only 4.5% revenue growth.
Bearish
- Stock has run past consensus target: The average analyst target of $66.66 sits 5.5% below the current $70.54 price after the 55% three-month rally. With 25 analysts covering and a mean rating of 2.21, the Street is constructive but has not chased the stock higher, signaling the easy money has been made near term.
- Growth stuck at 4.5% with no acceleration: Q2 2026 revenue of $5.481 billion grew only 4.5% YoY and just 1.3% sequentially from Q1's $5.413 billion. This is well below the mid-to-high single-digit growth historically expected of tier-1 IT services and explains the persistent valuation discount to peers.
- GenAI cannibalization threat to legacy revenue: The core application development and maintenance business faces pricing pressure as GenAI automates traditional coding and support work. With Financial Services ($1.733 billion) and Healthcare ($1.572 billion) comprising the bulk of revenue, any AI-driven deflation in these verticals hits the largest profit pools directly.
- Extreme target dispersion signals uncertainty: Analyst targets range from $47 to $93, a spread of roughly 98% of the low, reflecting genuine disagreement about Cognizant's growth trajectory. The $47 low target implies 33% downside and prices in margin compression and continued share loss to Accenture, Infosys, and TCS.
CTSH Technical Analysis
Cognizant is in a powerful recovery uptrend following a severe earlier drawdown, with the stock up 3.69% over the trailing year but a striking 55.20% over the past three months, and 28.00% over six months. At $70.54, the shares sit at roughly 66.8% of the 52-week range of $37.08 to $87.03, meaning price has reclaimed two-thirds of its annual band after bottoming near the lows in late June. The 1-year gain of just 3.69% versus the S&P 500's 13.13% (relative strength of -9.44%) confirms the stock spent most of the year as a laggard, so the current positioning reflects a momentum-driven repair rather than a sustained leadership trend. The 52-week range itself is unusually wide at roughly 135% of the low, and the -55.33% max drawdown underscores how violent the de-rating was before this rebound. Short-term momentum is decisively positive and accelerating: the 1-month change of 19.28% and 3-month change of 55.20% both dwarf the 1-year figure of 3.69%, a classic signature of trend reversal rather than continuation. Relative strength versus SPY is +20.30% over one month and +52.35% over three months, a dramatic swing from the -24.66% YTD relative underperformance, indicating aggressive mean-reversion buying into a previously oversold name. The most recent session showed a -4.31% pullback from $73.72 to $70.54 on elevated volume of 6.35 million shares, a short-term overbought shakeout after a parabolic run from the $57 area in late September to $73.72 on October 22. Key resistance sits at the October 22 high of $73.72 and then the 52-week high of $87.03; a breakout above $73.72 would confirm the recovery as a new uptrend, while support rests at the $56-$57 consolidation zone from late September and ultimately the $37.08 52-week low. With a beta of 0.851, Cognizant is roughly 15% less volatile than the market, which tempers position-sizing risk but also implies the 55% three-month move is unusually large for this name and may be vulnerable to profit-taking.
Beta
0.85
0.85x market volatility
Max Drawdown
-55.3%
Largest decline past year
52-Week Range
$37-$87
Price range past year
Annual Return
-2.2%
Cumulative gain past year
| Period | CTSH Return | S&P 500 |
|---|---|---|
| 1m | +16.9% | +0.9% |
| 3m | +23.1% | +4.1% |
| 6m | +26.6% | +7.2% |
| 1y | -2.2% | +12.4% |
| ytd | -18.4% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTSH Fundamental Analysis
Revenue is growing but at a modest pace: Q2 2026 revenue of $5.481 billion rose 4.5% YoY versus $5.245 billion in Q2 2025, continuing a steady but unspectacular trajectory from $5.333 billion in Q4 2025 and $5.413 billion in Q1 2026. The sequential trend is essentially flat-to-slightly-up, with Q2 2026 up just 1.3% from Q1 2026's $5.413 billion, indicating no meaningful acceleration. By segment, Financial Services is the largest contributor at $1.733 billion, followed by Healthcare at $1.572 billion, Products and Resources at $1.322 billion, and Communication, Media and Technology at $854 million; the concentration in financial services and healthcare exposes growth to client budget cycles in those verticals. The 4.5% growth rate is below the mid-to-high single-digit growth investors historically expected from tier-1 IT services, which explains the persistent valuation discount and the market's skepticism about the durability of the current re-rating. Profitability remains solid and is improving: Q2 2026 net income was $636 million on a 33.37% gross margin and 11.60% net margin, with operating income of $874 million (15.95% operating margin). Gross margin has been stable in the 33-34% band across recent quarters (33.37% in Q2 2026, 29.63% in Q1 2026, 31.11% in Q4 2025, 33.87% in Q3 2025), while operating margin has held near 16%, reflecting disciplined SG&A control at $728 million in Q2 2026. The Q3 2025 anomaly of $274 million net income (5.06% net margin) was driven by a $613 million tax charge, not operational deterioration, and the subsequent quarters confirm normalized earnings power of roughly $1.34-$1.39 diluted EPS per quarter. The balance sheet is a clear strength: debt-to-equity of just 0.105, a current ratio of 2.34, and interest coverage above 100x leave Cognizant with minimal leverage risk. Free cash flow is robust at $2.598 billion TTM, though quarterly FCF is lumpy ($459 million in Q2 2026, $198 million in Q1 2026, $781 million in Q4 2025), and the company is deploying cash aggressively into buybacks ($1.163 billion in Q2 2026 alone) and acquisitions ($604 million in Q2 2026, $730 million in Q1 2026). ROE of 14.85% and ROA of 10.74% are respectable for the sector, and the $1.038 billion cash balance plus strong operating cash flow ($558 million in Q2 2026) means growth is internally funded with room for continued capital returns.
Quarterly Revenue
$5.5B
2026-06
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
33.4%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTSH Overvalued?
Because Cognizant is solidly profitable (Q2 2026 net income of $636 million), the PE ratio is the appropriate primary metric. The stock trades at 18.20x trailing earnings but only 11.13x forward earnings, a 39% compression that implies the market expects meaningful EPS growth toward the consensus estimate of $6.26 for the forward period. That wide trailing-to-forward gap is the single most important valuation signal here: at 11.1x forward, the market is pricing Cognizant as a low-growth value stock despite the recent price surge, suggesting either the rebound has room to run on multiple expansion or the market doubts the forward earnings estimate. Against sector benchmarks, the picture is mixed: the 18.20x trailing PE and 1.89x PS are modest for technology but roughly in line with IT services peers, while the 9.49x EV/EBITDA and 1.52x EV/Sales sit at the low end of the range for scaled IT services firms, consistent with Cognizant's below-peer growth profile. The 2.66x price-to-book and 13.85x price-to-cash-flow are unremarkable, and the 20.57 PEG ratio is distorted by a near-zero trailing EPS figure in the metrics feed and should be disregarded in favor of the forward PE. On balance, the stock screens as fairly valued to modestly cheap versus its own history and the broader tech sector, with the discount defensible given 4.5% growth but arguably too wide if margins hold and buybacks continue shrinking the share count. Historically, Cognizant's PE has ranged from roughly 7.1x (Q2 2026 trough) to 29.9x (Q3 2025 tax-distorted peak), with the more normal band in the 14x-18x area across 2024-2025; at 18.20x trailing, the stock is near the upper end of its recent historical band, while the 11.13x forward multiple sits near the low end. This divergence suggests the market is pricing in optimistic near-term earnings delivery but remains unwilling to pay a premium trailing multiple, a classic setup for a value re-rating if execution holds or a sharp de-rating if growth stalls.
PE
18.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but real. Revenue growth of 4.5% YoY with only 1.3% sequential expansion means the company depends on cost control and buybacks rather than organic expansion to grow EPS, and gross margin has oscillated between 29.63% and 33.87% over the past four quarters, showing sensitivity to revenue mix and utilization. Quarterly free cash flow is lumpy ($459 million in Q2 2026 versus $198 million in Q1 2026 and $781 million in Q4 2025), and the company is spending heavily on acquisitions ($604 million in Q2 2026, $730 million in Q1 2026) that carry integration risk. Concentration in Financial Services ($1.733 billion) and Healthcare ($1.572 billion) exposes results to client budget cycles in those two verticals, which together represent roughly 60% of revenue. Market and competitive risks center on valuation compression and AI disruption. At 18.20x trailing PE the stock sits near the upper end of its recent 14x-18x historical band, so any growth disappointment leaves little multiple cushion, while the 11.13x forward multiple depends entirely on the $6.26 EPS estimate being met. Competition from Accenture, Infosys, TCS, and Wipro on large multi-year contracts is intensifying, and GenAI-driven pricing pressure could deflate traditional application maintenance revenue. Beta of 0.851 offers some macro insulation, but the stock's -13.21% YTD performance versus SPY's +11.45% shows it has been a sector-rotation casualty, and the 5.15 short ratio indicates meaningful bearish positioning. The worst-case scenario is a growth scare combined with an AI-disruption narrative: Q3 bookings miss, forward EPS guidance is cut below $6.00, and the stock de-rates back toward the $47 analyst low. From $70.54, that is roughly -33%, and a full retest of the $37.08 52-week low would represent a -47% loss, consistent with the -55.33% max drawdown already experienced this cycle. Such a scenario would likely be triggered by Financial Services clients freezing discretionary spend while GenAI tools compress pricing on renewals.
FAQ
The most severe risk is GenAI cannibalization of legacy application development and maintenance revenue, which could compress pricing and margins across the Financial Services ($1.733 billion) and Healthcare ($1.572 billion) verticals that dominate the revenue base. Second is growth risk: 4.5% YoY revenue growth with only 1.3% sequential expansion means the $6.26 forward EPS estimate depends on buybacks and cost control, and any bookings miss would force estimate cuts. Third is valuation compression — at 18.20x trailing PE near the top of its historical band, there is little multiple cushion, and the stock already trades 5.5% above the $66.66 consensus target. Fourth is competitive share loss to Accenture, Infosys, TCS, and Wipro on large multi-year contracts, compounded by the wide $47-$93 analyst target dispersion that signals genuine uncertainty about the growth trajectory.
The 12-month forecast splits into three scenarios: a 25% probability bull case targeting $87-$93 (the 52-week high and analyst high target) if forward EPS of $6.26 is beaten and bookings accelerate above 5%; a 50% probability base case targeting $63-$72 around the $66.66 consensus if revenue grows 4%-5% and margins hold near 16%; and a 25% probability bear case targeting $47-$55 (the analyst low target) if a growth scare forces EPS guidance below $6.00. The base case is most likely because the 11x-12x forward multiple already reflects the modest growth profile and buybacks mechanically support EPS. The key assumption behind the base case is that the $6.26 forward EPS estimate survives the next two earnings reports intact.
CTSH screens as fairly valued to modestly undervalued, with the answer depending heavily on which multiple you weight. At 18.20x trailing PE the stock sits near the upper end of its recent 14x-18x historical band, suggesting limited trailing-multiple upside, but at 11.13x forward EPS of $6.26 it trades at the low end of that range and well below the broader technology sector. The 9.49x EV/EBITDA and 1.52x EV/Sales are at the low end for scaled IT services peers like Accenture and Infosys, a discount defensible given 4.5% growth but arguably too wide if margins hold. The market is effectively pricing Cognizant as a low-growth value stock while expecting 39% EPS growth to $6.26 — a divergence that resolves either through multiple expansion if execution holds or a sharp de-rating if growth stalls.
From a risk/reward perspective, CTSH is a reasonable but no-longer-compelling buy at $70.54. The 11.13x forward PE against $6.26 of estimated EPS is cheap for a company with $2.598 billion in TTM free cash flow and a 0.105 debt-to-equity ratio, and the 1.5% dividend plus aggressive buybacks provide a return floor. However, the stock has already rallied 55.20% in three months and now trades 5.5% above the $66.66 consensus target, so near-term upside to the average analyst view is negative. The biggest downside risk is a growth scare that sends shares toward the $47 low target, roughly -33%. It is a good buy for value and income investors willing to accumulate on pullbacks toward $60-$63 (about 10x forward EPS), but growth investors should look elsewhere given the 4.5% revenue growth rate.
CTSH is better suited to a long-term holding period of at least 12-24 months than to short-term trading. The low beta of 0.851 and 1.5% dividend yield fit a defensive, income-oriented allocation, and the buyback-driven EPS compounding (diluted shares down 6.2% from 497 million to 466 million) rewards patience. However, the stock's -55.33% max drawdown and 135% 52-week range show it is not immune to violent swings, and the recent 55.20% three-month rally means short-term entry carries meaningful pullback risk toward the $56-$57 support zone. A concrete minimum holding period of 12 months allows the forward EPS estimate to be validated and captures at least one full buyback cycle, while short-term traders should wait for a confirmed breakout above $73.72 or a pullback to $60-$63 before entering.